CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-06 | ALTSHULER DAVID EVP, Global Research and CSO | Exercise or conversion | +1,304 | $187.53 | $245K | 69,949 |
| 2023-02-06 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −12 | $300.39 | $4K | 69,937 |
| 2023-02-06 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −70 | $302.00 | $21K | 69,867 |
| 2023-02-06 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −100 | $303.64 | $30K | 69,767 |
| 2023-02-06 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −349 | $305.08 | $106K | 69,418 |
| 2023-02-06 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −620 | $306.70 | $190K | 68,798 |
| 2023-02-06 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −153 | $309.06 | $47K | 68,645 |
| 2023-02-06 | ALTSHULER DAVID EVP, Global Research and CSO | Exercise or conversion · Stock Option (Right to Buy) | −1,304 | 0 | ||
| 2023-02-02 | LEIDEN JEFFREY M Executive Chairman | Shares withheld for taxes | −3,578 | $317.83 | $1.1M | 75,423 |
| 2023-02-01 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Grant or award | +10,324 | 53,188 | ||
| 2023-02-01 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Grant or award | +10,262 | 63,450 | ||
| 2023-02-01 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Grant or award | +9,440 | 72,890 | ||
| 2023-02-01 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Grant or award | +6,194 | 52,284 | ||
| 2023-02-01 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Grant or award | +10,262 | 62,546 | ||
| 2023-02-01 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Grant or award | +7,866 | 70,412 | ||
| 2023-02-01 | Sanna Bastiano EVP, Cell & Genetic Therapies | Grant or award | +9,092 | 47,090 | ||
| 2023-02-01 | Sanna Bastiano EVP, Cell & Genetic Therapies | Grant or award | +12,314 | 59,404 | ||
| 2023-02-01 | Sanna Bastiano EVP, Cell & Genetic Therapies | Grant or award | +7,866 | 67,270 | ||
| 2023-02-01 | Sachdev Amit EVP, Chief Patient Officer | Grant or award | +10,324 | 63,676 | ||
| 2023-02-01 | Sachdev Amit EVP, Chief Patient Officer | Grant or award | +8,210 | 71,886 |
Page 38 of 40 · 781 trades